BioNTech highlights lung cancer pipeline ahead of WCLC 2026
BioNTech says it will present first global lung cancer data for pumitamig with elfetabart drozuntecan from a Phase 1/2 trial and updated overall survival data from Phase 3 PRESERVE-003 for gotistobart.